LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

43.46 -2.69

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

43.21

Max

44.64

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+24.31% upside

Turustatistika
By TradingEconomics
Turukapital	19M 3.2B
Eelmine avamishind	46.15
Eelmine sulgemishind	43.46

Uudiste sentiment

By Acuity

50%

166 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. dets 2025, 21:16 UTC

Omandamised, ülevõtmised, äriostud

Marsh McLennan Agency Acquires Three Hawaii-Based Insurance Brokerages

1. dets 2025, 18:51 UTC

Suurimad hinnamuutused turgudel

Shopify Stock Falls on Cyber Monday System Outages

1. dets 2025, 23:47 UTC

Market Talk

Nikkei May Rise on Bargain Hunting -- Market Talk

1. dets 2025, 23:27 UTC

Omandamised, ülevõtmised, äriostud

Genting Bhd. Stake in Genting Malaysia Now at 73.13% Vs. 49.36% Ahead of Take Private Offer Made in October

1. dets 2025, 23:26 UTC

Omandamised, ülevõtmised, äriostud

Genting Bhd.: Offer to Take Genting Malaysia Private Closed on Dec.1

1. dets 2025, 23:25 UTC

Omandamised, ülevõtmised, äriostud

Bitcoin Rout Picks Up Steam as Investors Fret Over a New 'Crypto Winter' -- WSJ

1. dets 2025, 21:52 UTC

Omandamised, ülevõtmised, äriostud

Wood Partners Announces Itochu Corp. Purchase of 19.5% of Wood Partners

1. dets 2025, 21:42 UTC

Omandamised, ülevõtmised, äriostud

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

1. dets 2025, 21:41 UTC

Market Talk

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1. dets 2025, 21:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. dets 2025, 21:41 UTC

Market Talk

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1. dets 2025, 21:17 UTC

Omandamised, ülevõtmised, äriostud

Commercial Metals Expects to Close Foley Products Deal by End of 2025 >CMC

1. dets 2025, 21:17 UTC

Omandamised, ülevõtmised, äriostud

Commercial Metals Completes Acquisition of Concrete Pipe & Precast for $675M Cash >CMC

1. dets 2025, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Commercial Metals Completes Acquisition Of Concrete Pipe & Precast, LLC >CMC

1. dets 2025, 20:15 UTC

Market Talk

Natural Gas Turns Positive Amid Mixed Weather Trends -- Market Talk

1. dets 2025, 20:00 UTC

Omandamised, ülevõtmised, äriostud

Marsh McLennan Agency Acquires Three Hawai'i-based Insurance Brokerages >MMC

1. dets 2025, 18:54 UTC

Market Talk

Silver Hits New Record As Momentum Continues -- Market Talk

1. dets 2025, 18:46 UTC

Market Talk

Luxury Seen With Accelerating Growth Next Year -- Market Talk

1. dets 2025, 16:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. dets 2025, 16:41 UTC

Market Talk

Rapid Wage Growth in Canada to Keep BOC Sidelined -- Market Talk

1. dets 2025, 16:20 UTC

Market Talk

Yen Could Strengthen Further Against Dollar on Rate-Hike Prospects -- Market Talk

1. dets 2025, 16:00 UTC

Tulu

Strategy Helped Solve Its Bitcoin-Preferred Problem. Here's How. -- Barrons.com

1. dets 2025, 15:51 UTC

Omandamised, ülevõtmised, äriostud

Goldman Makes a $2 Billion Bet on 'Boomer Candy' -- WSJ

1. dets 2025, 15:47 UTC

Market Talk

Global Equities Roundup: Market Talk

1. dets 2025, 15:47 UTC

Market Talk

Airbus Guidance Is at Risk -- Market Talk

1. dets 2025, 15:46 UTC

Omandamised, ülevõtmised, äriostud

Synopsys Gets a New Investor. What to Know About Nvidia's Stake. -- Barrons.com

1. dets 2025, 15:33 UTC

Market Talk

Airbus Selloff May Be Overdone -- Market Talk

1. dets 2025, 15:26 UTC

Market Talk

Warming Forecast Pressures Natural Gas -- Market Talk

1. dets 2025, 15:23 UTC

Market Talk

Geopolitical Turmoil Supports Crude Oil -- Market Talk

1. dets 2025, 14:59 UTC

Omandamised, ülevõtmised, äriostud

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

24.31% tõus

12 kuu keskmine prognoos

Keskmine 55.59 USD 24.31%

Kõrge 65 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

166 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.